Government-Owned Inventions; Availability for Licensing, 58861-58862 [E7-20517]
Download as PDF
<![CDATA[
Federal Register / Vol. 72, No. 200 / Wednesday, October 17, 2007 / Notices
Inventors: Pradman Qasba, Boopathy
Ramakrishnan, Elizabeth Boeggman
(NCI).
Patent Status: PCT Patent Application
filed 22 Aug 2007 (HHS Reference No.
E–280–2007/0–PCT–01).
Licensing Status: Available for
exclusive or non-exclusive licensing.
Licensing Contact: Peter A. Soukas,
J.D.; 301/435–4646;
soukasp@mail.nih.gov
Collaborative Research Opportunity:
The CCR Nanobiology Program of the
National Cancer Institute is seeking
statements of capability or interest from
parties interested in collaborative
research to further develop, evaluate, or
commercialize glycosyltransferases.
Please contact John D. Hewes, Ph.D.,
Technology Transfer Specialist, NCI, at
(301) 435–3121 or hewesj@nail.nih.gov.
sroberts on PROD1PC70 with NOTICES
Targeting Poly-Gamma-Glutamic Acid
to Treat Staphylococcus Epidermidis
and Related Infections
Description of Invention: Over the
past decade, Staphylococcus
epidermidis has become the most
prevalent pathogen involved in
nosocomial infections. Usually an
innocuous commensal microorganism
on human skin, this member of the
coagulase-negative group of
staphylococci can cause severe infection
after penetration of the epidermal
protective barriers of the human body.
In the U.S. alone, S. epidermidis
infections on in-dwelling medical
devices, which represent the main type
of infection with S. epidermidis, cost
the public health system approximately
$1 billion per year. Importantly, S.
epidermidis is frequently resistant to
common antibiotics.
Immunogenic compositions and
methods for eliciting an immune
response against S. epidermidis and
other related staphylococci are claimed.
The immunogenic compositions can
include immunogenic conjugates of
poly-g-glutamic acid (such as gDLPGA)
polypeptides of S. epidermidis, or
related staphylococci that express a
gPGA polypeptide. The gPGA conjugates
elicit an effective immune response
against S. epidermidis, or other
staphylococci, in subjects to which the
conjugates are administered. A method
of treating an infection caused by a
Staphylococcus organism that expresses
cap genes is also disclosed. The method
can include selecting a subject who is at
risk of or has been diagnosed with the
infection by the Staphylococcus
organism which expresses gPGA from
the cap genes. Further, the expression of
a gPGA polypeptide by the organism can
then be altered.
VerDate Aug<31>2005
19:05 Oct 16, 2007
Jkt 214001
Application: Prophylactics against S.
epidermidis.
Developmental Status: Preclinical
studies have been performed.
Inventors: Michael Otto, Stanislava
Kocianova, Cuong Vuong, Jovanka
Voyich, Yufeng Yao, Frank DeLeo
(NIAID)
Publication: S Kocianova et al. Key
role of poly-gamma-DL-glutamic acid in
immune evasion and virulence of
Staphylococcus epidermidis. J Clin
Invest. 2005 Mar;115(3):688–694.
Patent Status: PCT Patent Application
No. PCT/US2006/026900 filed 10 Jul
2006 (HHS Reference No. E–263–2005/
0–PCT–02).
Licensing Status: Available for
exclusive or non-exclusive licensing.
Licensing Contact: Peter A. Soukas,
J.D.; 301/435–4646;
soukasp@mail.nih.gov
Collaborative Research Opportunity:
The National Institute of Allergy and
Infectious Diseases, Laboratory of
Human Bacterial Pathogenesis, is
seeking statements of capability or
interest from parties interested in
collaborative research to further
develop, evaluate, or commercialize the
use of poly-g-glutamic acid of
staphylococci. Please contact Dr.
Michael Otto at motto@niaid.nih.gov for
more information.
Dated: October 10, 2007.
Steven M. Ferguson,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. E7–20515 Filed 10–16–07; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
AGENCY:
SUMMARY: The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 207 to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
ADDRESSES: Licensing information and
copies of the U.S. patent applications
PO 00000
Frm 00058
Fmt 4703
Sfmt 4703
58861
listed below may be obtained by writing
to the indicated licensing contact at the
Office of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville,
Maryland 20852–3804; telephone: 301/
496–7057; fax: 301/402–0220. A signed
Confidential Disclosure Agreement will
be required to receive copies of the
patent applications.
Multiple Donor Tissue-Derived Large
IgM VH-Based Fab Human Antibody
Library
Description of Technology: Available
for licensing as a biological material for
either internal use or commercial
distribution is a human Fab
immunoglobulin/antibody fragment
phage display library. The library
contains 10 10 Fabs derived from the
peripheral blood of ten (10) healthy
human donors. The high quality of the
library was demonstrated in the
successful selection of high affinity
antibodies specific for Hendra and
Nipah viruses; however, the library is
useful for selecting a variety of antigen
specific immunoglobulin/antibody Fab
fragments especially for cancer or
viruses.
Applications: Antibody discovery—
Diagnostics, Therapeutics, Research
Reagents.
Advantages and Benefits: High
affinity multi-purpose antibodies.
Inventors: Dimiter S. Dimitrov (NCI)
et al.
Publications:
1. Zhang et al. Selection of a novel
gp41-specific HIV–1 neutralizing human
antibody by competitive antigen
panning. J Immunol Methods. 2006 Dec
20; 317(1–2):21–30. Epub 2006 Oct 16.
2. Zhu et al. Potent neutralization of
Hendra and Nipah viruses by human
monoclonal antibodies. J Virol. 2006
Jan;80(2):891–899.
3. Zhang et al. Human monoclonal
antibodies to the S glycoprotein and
related proteins as potential
therapeutics for SARS. Curr Opin Mol
Ther. 2005 Apr;7(2):151–156. Review.
Patent Status: HHS Reference No. E–
188–2007/0—Research Tool. Patent
protection is not being sought for this
technology.
Licensing Status: Available for nonexclusive licensing as biological
material.
Licensing Contact: Michael
Shmilovich, Esq.; 301/435–5019;
shmilovm@mail.nih.gov.
Collaborative Research Opportunity:
The NCI-Frederick is seeking statements
of capability or interest from parties
interested in collaborative research to
further develop, evaluate, or
commercialize therapeutic, diagnostic
E:\FR\FM\17OCN1.SGM
17OCN1
58862
Federal Register / Vol. 72, No. 200 / Wednesday, October 17, 2007 / Notices
or research reagent antibodies. Please
contact Thomas Stackhouse at
stackhot@mail.nih.gov or 301–846–5465
for more information.
sroberts on PROD1PC70 with NOTICES
Optical Slice Motion Tracker
Description of Technology: Available
for licensing and commercial
development is an apparatus that
adjusts the focal plane of a microscope
in order to track plane motion of a
sample. The apparatus includes a motor
that can change the focal plane by
moving the objective of the microscope
and a computer that reads image data
from the microscope photomultiplier
tube (PMT). The apparatus uses time
between images to perform a navigator
function comprising quickly scanning
many nearby focal planes with a
minimum field of view and utilizing
pattern matching to calculate an offset
distance to adjust the focal plane. The
apparatus permits imaging of moving
structures, such as living tissue, over
time by compensating for motion in the
direction of the focal plane. The use of
navigator movement to track an
optically selected slice can be
implemented in any of various research
or medical devices.
Applications: Microscopy; Cell
biology.
Development Status: Early-stage;
Prototype.
Inventors: James L. Schroeder
(NHLBI), Robert S. Balaban (NHLBI),
Thomas J. Pohida (CIT), John W.
Kakareka (CIT), Randall Pursley (CIT).
Patent Status: U.S. Provisional
Application No. 60/904,683 filed 02 Mar
2007 (HHS Reference No. E–114–2007/
0–US–01). The issued and pending
patent rights are solely owned by the
United States Government.
Licensing Status: Licensing on a nonexclusive basis and exclusive to
qualified applicants whose application
for licensure complies with 37 CFR 404.
Licensing Contact: Michael A.
Shmilovich, Esq.; 301/435–5019;
shmilovm@mail.nih.gov.
Collaborative Research Opportunity:
The NHLBI is seeking statements of
capability or interest from parties
interested in collaborative research to
further develop, evaluate, or
commercialize the optical slice motion
tracker. Please contact Lili Portilla at
301–594–4273 or via e-mail at
Lilip@nih.gov for more information.
A Fundus Photo-Stimulation System
and Method
Description of Technology: Available
for licensing and commercial
development is an optical system which
permits targeted photo-stimulation of
the retina by positioning the stimulus
VerDate Aug<31>2005
19:05 Oct 16, 2007
Jkt 214001
location under visual guidance through
a fundus camera. The system is
designed to elicit, under direct infra-red
visual control of stimulus size and
position in the retina,
electroretinograms (ERGs) in response to
photo-stimulation from selected regions
of the retina, as well as to present small
light stimuli to a selected area to explore
visual sensitivity properties. For
example, the detected ERGs can be the
basis for diagnosing or characterizing
patient retina with early stage retinal
disease versus healthy retina from the
opposite eye. The system can be
mounted on commercially available
fundus cameras that have infra-red
capabilities (or would accept infra-red
bandpass filtering of their retinal
illumination output) and will accept a
near IR CCD camera connected to a TV
mounted on the photographic-camera
port.
The optical system can comprise a
targeting light path originating from a
deep red laser and a stimulus light path
originating from a Xenon strobe lamp.
Both light paths are brought into
collinear alignment by a beam splitter.
The light paths are transmitted to the
eye through an adjustable turning mirror
and a focusing lens. A beam splitter in
front of the fundus camera objective
lens merges the optical path of the
fundus camera with that of the targeting
optical path and the stimulus light path.
The merged beams are brought to a
focus at or close to the lens of the eye.
A movable aperture is interposed on the
collinear beams and imaged on the
retina such that its lateral position and
size can be adjusted by the operator to
select the retinal area to be photostimulated. This arrangement ensures
that the stimulating light flashes
illuminate the same field as was
selected using the deep red targeting
laser. This system permits projection of
repeatable visible-light flashes with
variable size and location onto the
retina.
Applications: Diagnosis of retinal
disease; Electroretinograms.
Development Status: Early-stage;
Prototype available.
Inventors: Paul Smith (ORS), Edward
Wellner (ORS), Francisco de Monasterio
(NEI).
Patent Status: U.S. Provisional
Application No. 60/935,107 filed 26 Jul
2007 (HHS Reference No. E–279–2006/
0–US–01). The pending patent rights are
solely owned by the United States
Government.
Licensing Status: Available for
licensing and commercialization. Nonexclusive rights are available. Exclusive
rights may be available to qualified
PO 00000
Frm 00059
Fmt 4703
Sfmt 4703
applicants and are subject to the
provisions set forth in 37 CFR 404.7.
Licensing Contact: Michael A.
Shmilovich, Esq.; 301/435–5019;
shmilovm@mail.nih.gov.
Collaborative Research Opportunity:
The Laboratory of Bioengineering and
Physical Science, NIBIB is seeking
statements of capability or interest from
parties interested in collaborative
research to further develop, evaluate, or
commercialize the Fundus PhotoStimulation System and Method. Please
contact Dr. Paul Smith at
smithpa@mail.nih.gov for more
information.
Dated: October 10, 2007.
Steven M. Ferguson,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. E7–20517 Filed 10–16–07; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
National Institutes of Health,
Public Health Service, HHS
ACTION: Notice.
AGENCY:
SUMMARY: The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 207 to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
ADDRESSES: Licensing information and
copies of the U.S. patent applications
listed below may be obtained by writing
to the indicated licensing contact at the
Office of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville,
Maryland 20852–3804; telephone: 301/
496–7057; fax: 301/402–0220. A signed
Confidential Disclosure Agreement will
be required to receive copies of the
patent applications.
Method for Inducing T-Cell
Proliferation
Description of Technology: This
technology relates to the use of thymic
stromal lymphopoietin (TSLP) to induce
CD4+ T cell proliferation. This
proliferation could be of particular
E:\FR\FM\17OCN1.SGM
17OCN1
]]>Agencies
[Federal Register Volume 72, Number 200 (Wednesday, October 17, 2007)]
[Notices]
[Pages 58861-58862]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E7-20517]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, Public Health Service, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by an agency of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 207 to achieve expeditious commercialization of results
of federally-funded research and development. Foreign patent
applications are filed on selected inventions to extend market coverage
for companies and may also be available for licensing.
ADDRESSES: Licensing information and copies of the U.S. patent
applications listed below may be obtained by writing to the indicated
licensing contact at the Office of Technology Transfer, National
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville,
Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A
signed Confidential Disclosure Agreement will be required to receive
copies of the patent applications.
Multiple Donor Tissue-Derived Large IgM VH-Based Fab Human
Antibody Library
Description of Technology: Available for licensing as a biological
material for either internal use or commercial distribution is a human
Fab immunoglobulin/antibody fragment phage display library.
The library contains 10 \10\ Fabs derived from the
peripheral blood of ten (10) healthy human donors. The high quality of
the library was demonstrated in the successful selection of high
affinity antibodies specific for Hendra and Nipah viruses; however, the
library is useful for selecting a variety of antigen specific
immunoglobulin/antibody Fab fragments especially for cancer
or viruses.
Applications: Antibody discovery--Diagnostics, Therapeutics,
Research Reagents.
Advantages and Benefits: High affinity multi-purpose antibodies.
Inventors: Dimiter S. Dimitrov (NCI) et al.
Publications:
1. Zhang et al. Selection of a novel gp41-specific HIV-1
neutralizing human antibody by competitive antigen panning. J Immunol
Methods. 2006 Dec 20; 317(1-2):21-30. Epub 2006 Oct 16.
2. Zhu et al. Potent neutralization of Hendra and Nipah viruses by
human monoclonal antibodies. J Virol. 2006 Jan;80(2):891-899.
3. Zhang et al. Human monoclonal antibodies to the S glycoprotein
and related proteins as potential therapeutics for SARS. Curr Opin Mol
Ther. 2005 Apr;7(2):151-156. Review.
Patent Status: HHS Reference No. E-188-2007/0--Research Tool.
Patent protection is not being sought for this technology.
Licensing Status: Available for non-exclusive licensing as
biological material.
Licensing Contact: Michael Shmilovich, Esq.; 301/435-5019;
shmilovm@mail.nih.gov.
Collaborative Research Opportunity: The NCI-Frederick is seeking
statements of capability or interest from parties interested in
collaborative research to further develop, evaluate, or commercialize
therapeutic, diagnostic
[[Page 58862]]
or research reagent antibodies. Please contact Thomas Stackhouse at
stackhot@mail.nih.gov or 301-846-5465 for more information.
Optical Slice Motion Tracker
Description of Technology: Available for licensing and commercial
development is an apparatus that adjusts the focal plane of a
microscope in order to track plane motion of a sample. The apparatus
includes a motor that can change the focal plane by moving the
objective of the microscope and a computer that reads image data from
the microscope photomultiplier tube (PMT). The apparatus uses time
between images to perform a navigator function comprising quickly
scanning many nearby focal planes with a minimum field of view and
utilizing pattern matching to calculate an offset distance to adjust
the focal plane. The apparatus permits imaging of moving structures,
such as living tissue, over time by compensating for motion in the
direction of the focal plane. The use of navigator movement to track an
optically selected slice can be implemented in any of various research
or medical devices.
Applications: Microscopy; Cell biology.
Development Status: Early-stage; Prototype.
Inventors: James L. Schroeder (NHLBI), Robert S. Balaban (NHLBI),
Thomas J. Pohida (CIT), John W. Kakareka (CIT), Randall Pursley (CIT).
Patent Status: U.S. Provisional Application No. 60/904,683 filed 02
Mar 2007 (HHS Reference No. E-114-2007/0-US-01). The issued and pending
patent rights are solely owned by the United States Government.
Licensing Status: Licensing on a non-exclusive basis and exclusive
to qualified applicants whose application for licensure complies with
37 CFR 404.
Licensing Contact: Michael A. Shmilovich, Esq.; 301/435-5019;
shmilovm@mail.nih.gov.
Collaborative Research Opportunity: The NHLBI is seeking statements
of capability or interest from parties interested in collaborative
research to further develop, evaluate, or commercialize the optical
slice motion tracker. Please contact Lili Portilla at 301-594-4273 or
via e-mail at Lilip@nih.gov for more information.
A Fundus Photo-Stimulation System and Method
Description of Technology: Available for licensing and commercial
development is an optical system which permits targeted photo-
stimulation of the retina by positioning the stimulus location under
visual guidance through a fundus camera. The system is designed to
elicit, under direct infra-red visual control of stimulus size and
position in the retina, electroretinograms (ERGs) in response to photo-
stimulation from selected regions of the retina, as well as to present
small light stimuli to a selected area to explore visual sensitivity
properties. For example, the detected ERGs can be the basis for
diagnosing or characterizing patient retina with early stage retinal
disease versus healthy retina from the opposite eye. The system can be
mounted on commercially available fundus cameras that have infra-red
capabilities (or would accept infra-red bandpass filtering of their
retinal illumination output) and will accept a near IR CCD camera
connected to a TV mounted on the photographic-camera port.
The optical system can comprise a targeting light path originating
from a deep red laser and a stimulus light path originating from a
Xenon strobe lamp. Both light paths are brought into collinear
alignment by a beam splitter. The light paths are transmitted to the
eye through an adjustable turning mirror and a focusing lens. A beam
splitter in front of the fundus camera objective lens merges the
optical path of the fundus camera with that of the targeting optical
path and the stimulus light path. The merged beams are brought to a
focus at or close to the lens of the eye. A movable aperture is
interposed on the collinear beams and imaged on the retina such that
its lateral position and size can be adjusted by the operator to select
the retinal area to be photo-stimulated. This arrangement ensures that
the stimulating light flashes illuminate the same field as was selected
using the deep red targeting laser. This system permits projection of
repeatable visible-light flashes with variable size and location onto
the retina.
Applications: Diagnosis of retinal disease; Electroretinograms.
Development Status: Early-stage; Prototype available.
Inventors: Paul Smith (ORS), Edward Wellner (ORS), Francisco de
Monasterio (NEI).
Patent Status: U.S. Provisional Application No. 60/935,107 filed 26
Jul 2007 (HHS Reference No. E-279-2006/0-US-01). The pending patent
rights are solely owned by the United States Government.
Licensing Status: Available for licensing and commercialization.
Non-exclusive rights are available. Exclusive rights may be available
to qualified applicants and are subject to the provisions set forth in
37 CFR 404.7.
Licensing Contact: Michael A. Shmilovich, Esq.; 301/435-5019;
shmilovm@mail.nih.gov.
Collaborative Research Opportunity: The Laboratory of
Bioengineering and Physical Science, NIBIB is seeking statements of
capability or interest from parties interested in collaborative
research to further develop, evaluate, or commercialize the Fundus
Photo-Stimulation System and Method. Please contact Dr. Paul Smith at
smithpa@mail.nih.gov for more information.
Dated: October 10, 2007.
Steven M. Ferguson,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. E7-20517 Filed 10-16-07; 8:45 am]
BILLING CODE 4140-01-P
